+86-13524779951 sales@x-mobio.com
  Anti-tumor series
  Antithrombotic series
  Anti-HCV series
  Rheumatism series
  Anti-diabetic series
  Nervous system series
  Featured products

This product is in stock,please ask for price.
If you have any question, please send the email to sales@x-mobio.com for the availability.We will reply to you as soon as possible.
Shipment: Products are shipped via FedEx Express.
PRT-060318, also known as PRT318 or P142–76, is a novel selective inhibitor of the tyrosine kinase Syk, as an approach to HIT treatment. PRT318 completely inhibited HIT immune complex-induced aggregation of both human and transgenic HIT mouse platelets. Transgenic HIT model mice were treated with KKO, a mouse monoclonal HIT-like antibody, and heparin. The experimental group received orally dosed PRT318, whereas the control group received vehicle. Nadir platelet counts of PRT318-treated mice were significantly higher than those of control mice. When examined with a novel thrombosis visualization technique, mice treated with PRT318 had significantly reduced thrombosis. 
Chemical Structure
Chemical Name
Theoretical Analysis
XingMo Cat#:XM094 
Product Name:PRT-060318 
Synonyms:PRT060318; PRT 060318; PRT-060318; PRT318; PRT-318; PRT 318; P14-276. 
Chemical Formula:C18H24N6O 
Exact Mass:340.20116 
Molecular Weight:340.42 
Technical Data

WARNING: This product is for research use only, not for human or veterinary use

Tel: +8613524779951  QQ: 点击这里给我发消息
Email: sales@x-mobio.com   Web: www.x-mobio.com  沪ICP备17047952号-1
Copyright 2017 Shanghai xingMo Biotechnology Co., Ltd. All rights reserved. Supported by www.hxchem.net